Literature DB >> 22778837

Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.

Travis T Wager1, Xinjun Hou, Patrick R Verhoest, Anabella Villalobos.   

Abstract

The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pK(a))), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = 11 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.

Entities:  

Keywords:  CNS MPO; CNS candidates; CNS drugs; Harrington optimization; Madin−Darby canine kidney; Multiparameter optimization (MPO); P-glycoprotein; Unbound intrinsic clearance; cellular toxicity; central nervous system (CNS); desirability score; dofetilide binding; drug−drug interactions; high-throughput screening; human liver microsome stability; hydrogen bond donor; lipophilicity; molecular weight; most basic pKa; multivariant optimization; passive permeability; polarity; topological polar surface area; transformed human liver epithelial cells

Mesh:

Substances:

Year:  2010        PMID: 22778837      PMCID: PMC3368654          DOI: 10.1021/cn100008c

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  20 in total

1.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

Authors:  Travis T Wager; Ramalakshmi Y Chandrasekaran; Xinjun Hou; Matthew D Troutman; Patrick R Verhoest; Anabella Villalobos; Yvonne Will
Journal:  ACS Chem Neurosci       Date:  2010-03-25       Impact factor: 4.418

Review 2.  The influence of drug-like concepts on decision-making in medicinal chemistry.

Authors:  Paul D Leeson; Brian Springthorpe
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

3.  Identifying promising compounds in drug discovery: genetic algorithms and some new statistical techniques.

Authors:  Abhyuday Mandal; Kjell Johnson; C F Jeff Wu; Dirk Bornemeier
Journal:  J Chem Inf Model       Date:  2007-04-11       Impact factor: 4.956

Review 4.  The influence of lead discovery strategies on the properties of drug candidates.

Authors:  György M Keserü; Gergely M Makara
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

5.  Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

Authors:  Natilie A Hosea; Wendy T Collard; Susan Cole; Tristan S Maurer; Rick X Fang; Hannah Jones; Shefali M Kakar; Yasuhiro Nakai; Bill J Smith; Rob Webster; Kevin Beaumont
Journal:  J Clin Pharmacol       Date:  2009-03-19       Impact factor: 3.126

6.  Physiochemical drug properties associated with in vivo toxicological outcomes.

Authors:  Jason D Hughes; Julian Blagg; David A Price; Simon Bailey; Gary A Decrescenzo; Rajesh V Devraj; Edmund Ellsworth; Yvette M Fobian; Michael E Gibbs; Richard W Gilles; Nigel Greene; Enoch Huang; Teresa Krieger-Burke; Jens Loesel; Travis Wager; Larry Whiteley; Yao Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-07-24       Impact factor: 2.823

7.  Lead- and drug-like compounds: the rule-of-five revolution.

Authors:  Christopher A Lipinski
Journal:  Drug Discov Today Technol       Date:  2004-12

8.  Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.

Authors:  Matt Deacon; David Singleton; Nikki Szalkai; Rodger Pasieczny; Chris Peacock; David Price; James Boyd; Helen Boyd; Jill V Steidl-Nichols; Christine Williams
Journal:  J Pharmacol Toxicol Methods       Date:  2006-10-18       Impact factor: 1.950

Review 9.  Research perspectives for pre-screening alternatives to animal experimentation: on the relevance of cytotoxicity measurements, barrier passage determinations and high throughput screening in vitro to select potentially hazardous compounds in large sets of chemicals.

Authors:  Erik Walum; Jan Hedander; Per Garberg
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-01       Impact factor: 4.219

Review 10.  The impact of drug-induced QT interval prolongation on drug discovery and development.

Authors:  Bernard Fermini; Anthony A Fossa
Journal:  Nat Rev Drug Discov       Date:  2003-06       Impact factor: 84.694

View more
  194 in total

1.  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Authors:  Alan P Kozikowski; Sida Shen; Marta Pardo; Maurício T Tavares; Dora Szarics; Veronick Benoy; Chad A Zimprich; Zsófia Kutil; Guiping Zhang; Cyril Bařinka; Matthew B Robers; Ludo Van Den Bosch; James H Eubanks; Richard S Jope
Journal:  ACS Chem Neurosci       Date:  2018-12-14       Impact factor: 4.418

2.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

3.  Drug discovery: Chemical beauty contest.

Authors:  Paul Leeson
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

Review 4.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry.

Authors:  Michael M Hann; György M Keserü
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

Review 5.  The influence of the 'organizational factor' on compound quality in drug discovery.

Authors:  Paul D Leeson; Stephen A St-Gallay
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

6.  Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.

Authors:  ThanhTruc Pham; Madeline Walden; Christopher Butler; Rosario Diaz-Gonzalez; Guiomar Pérez-Moreno; Gloria Ceballos-Pérez; Veronica Gomez-Pérez; Raquel García-Hernández; Henry Zecca; Emma Krakoff; Brian Kopec; Ogar Ichire; Caden Mackenzie; Marika Pitot; Luis Miguel Ruiz; Francisco Gamarro; Dolores González-Pacanowska; Miguel Navarro; Amy B Dounay
Journal:  Bioorg Med Chem Lett       Date:  2017-07-11       Impact factor: 2.823

7.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Authors:  Chad M Kormos; Pauline W Ondachi; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

Review 8.  The significance of acid/base properties in drug discovery.

Authors:  David T Manallack; Richard J Prankerd; Elizabeth Yuriev; Tudor I Oprea; David K Chalmers
Journal:  Chem Soc Rev       Date:  2013-01-21       Impact factor: 54.564

9.  Expansion of the structure-activity relationships of BACE1 inhibitors by harnessing diverse building blocks prepared using a unified synthetic approach.

Authors:  Joan Mayol-Llinàs; Shiao Chow; Adam Nelson
Journal:  Medchemcomm       Date:  2019-03-22       Impact factor: 3.597

Review 10.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.